See more : Toyo Wharf & Warehouse Co., Ltd. (9351.T) Income Statement Analysis – Financial Results
Complete financial analysis of Zealand Pharma A/S (ZLDPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zealand Pharma A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- Hiscox Ltd (HSX.L) Income Statement Analysis – Financial Results
- Celtic plc (CCPA.L) Income Statement Analysis – Financial Results
- Ginkgo Bioworks Holdings, Inc. WT (DNA-WT) Income Statement Analysis – Financial Results
- Mudanjiang Hengfeng Paper Co.,Ltd (600356.SS) Income Statement Analysis – Financial Results
- Dairei Co.,Ltd. (2883.T) Income Statement Analysis – Financial Results
Zealand Pharma A/S (ZLDPF)
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 342.79M | 103.99M | 292.57M | 353.31M | 41.33M | 37.98M | 139.78M | 234.78M | 187.68M | 153.77M | 6.57M | 223.57M | 142.28M | 87.36M | 25.32M | 56.26M | 59.92M |
| Cost of Revenue | 19.17M | 30.71M | 118.81M | 90.57M | 415.00K | 180.24M | 14.63M | 31.46M | 22.27M | 13.78M | 872.00K | 15.93M | 112.00K | 11.20M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 323.61M | 73.28M | 173.75M | 262.75M | 40.92M | -142.26M | 125.15M | 203.32M | 165.41M | 140.00M | 5.70M | 207.63M | 142.17M | 76.15M | 25.32M | 56.26M | 59.92M |
| Gross Profit Ratio | 94.41% | 70.47% | 59.39% | 74.37% | 99.00% | -374.60% | 89.53% | 86.60% | 88.14% | 91.04% | 86.74% | 92.87% | 99.92% | 87.18% | 100.00% | 100.00% | 100.00% |
| Research & Development | 684.90M | 614.04M | 588.45M | 604.08M | 561.42M | 438.22M | 324.67M | 268.16M | 214.96M | 180.04M | 164.47M | 182.76M | 126.94M | 151.28M | 93.09M | 85.76M | 105.14M |
| General & Administrative | 73.80M | 274.24M | 260.99M | 202.77M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Selling & Marketing | 16.05M | 32.30M | 375.27M | 285.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.85M | 306.54M | 636.26M | 488.03M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Other Expenses | 121.10M | 0.00 | -759.00K | -602.00K | -444.00K | 1.10B | 0.00 | 777.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 895.85M | 920.59M | 1.22B | 1.09B | 628.86M | 515.59M | 371.53M | 318.97M | 246.74M | 213.53M | 191.32M | 175.24M | 133.41M | 196.05M | 105.24M | 100.95M | 122.45M |
| Cost & Expenses | 915.03M | 920.59M | 1.34B | 1.18B | 629.28M | 695.82M | 386.16M | 350.42M | 269.00M | 227.31M | 192.19M | 191.17M | 133.52M | 196.05M | 105.24M | 100.95M | 122.45M |
| Interest Income | 45.32M | 6.54M | 44.00K | 895.00K | 5.41M | 4.26M | 2.05M | 592.00K | 139.00K | 719.00K | 3.04M | 5.63M | 6.56M | 4.13M | 4.32M | 11.21M | 0.00 |
| Interest Expense | 24.89M | 56.46M | 4.09M | 2.90M | 3.21M | 15.08M | 18.91M | 32.16M | 32.71M | 2.02M | 81.00K | 186.00K | 1.95M | 63.00K | 104.00K | 257.00K | 0.00 |
| Depreciation & Amortization | 25.09M | 30.71M | 25.12M | 42.69M | 13.54M | 4.51M | 4.76M | 5.41M | 6.22M | 5.93M | 5.91M | 5.32M | 4.13M | 4.13M | 3.69M | 3.28M | 0.00 |
| EBITDA | -658.89M | -665.26M | -711.85M | -627.94M | -562.64M | -442.00M | -246.28M | -118.27M | -81.25M | -64.54M | -177.68M | 41.92M | 14.68M | -104.57M | -76.25M | -44.69M | -62.53M |
| EBITDA Ratio | -192.22% | -639.76% | -332.94% | -246.80% | -1,361.23% | -1,761.72% | -176.19% | -50.37% | -45.11% | -43.50% | -2,687.30% | 19.39% | 13.67% | -119.71% | -284.06% | -79.43% | -104.35% |
| Operating Income | -572.24M | -816.60M | -1.05B | -828.76M | -587.94M | 652.39M | -246.38M | -115.65M | -81.33M | -73.54M | -185.62M | 32.40M | 8.76M | -108.70M | -79.93M | -44.69M | -62.53M |
| Operating Income Ratio | -166.94% | -785.30% | -358.96% | -234.57% | -1,422.45% | 1,717.86% | -176.27% | -49.26% | -43.33% | -47.82% | -2,823.52% | 14.49% | 6.16% | -124.43% | -315.67% | -79.43% | -104.35% |
| Total Other Income/Expenses | -136.63M | -134.89M | 25.43M | -47.29M | 11.27M | -27.33M | -31.39M | -43.76M | -38.51M | 1.05M | 1.94M | 3.98M | 4.61M | 4.06M | 4.86M | 10.96M | 7.53M |
| Income Before Tax | -708.87M | -972.04M | -1.03B | -839.65M | -576.68M | 625.06M | -277.77M | -159.41M | -119.83M | -72.49M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Income Before Tax Ratio | -206.79% | -934.78% | -351.01% | -237.65% | -1,395.20% | 1,645.88% | -198.73% | -67.90% | -63.85% | -47.14% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| Income Tax Expense | -5.13M | -6.43M | -8.79M | 7.08M | -5.14M | 43.77M | -5.50M | -5.50M | -5.88M | -7.50M | 81.00K | 186.00K | 6.56M | 0.00 | 4.32M | -3.28M | 0.00 |
| Net Income | -703.74M | -965.61M | -1.02B | -846.73M | -571.54M | 581.28M | -272.27M | -153.91M | -113.96M | -64.99M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Net Income Ratio | -205.30% | -928.60% | -348.01% | -239.65% | -1,382.77% | 1,530.61% | -194.79% | -65.56% | -60.72% | -42.26% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| EPS | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.61 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| EPS Diluted | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.60 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| Weighted Avg Shares Out | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.69M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.63M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
| Weighted Avg Shares Out (Dil) | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.70M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.73M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
Zealand Pharma A/S (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
Source: https://incomestatements.info
Category: Stock Reports
What are the future financial projections for Zealand Pharma?
Zealand Pharma AS (OCSE:ZEAL) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $54.77 million, and the earnings are expected to come in at -$4.06 per share.
What is Zealand Pharma’s revenue for 2024?
Revenue estimates for Zealand Pharma AS (OCSE:ZEAL) have declined from $190.56 million to $163.57 million for the full year 2024 and from $0.83 billion to $0.73 billion for 2025 over the past 90 days.